TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy
Francesco Graziano(Ospedale Vincenzo Cervello), Annamaria Ruzzo(University of Urbino)
Cited by 24
Related Papers
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
|Nature Medicine|2018|282
A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer
|Annals of Oncology|2000|86
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
|British Journal of Cancer|2017|68